Abstract: A Bifidobacterium lactis BL-99 strain capable of enhancing immunity and the use thereof, which belongs to the technical field of microorganisms, is described. The Bifidobacterium lactis BL-99 provided by the present invention is deposited in China General Microbiological Culture Collection Center CGMCC on Apr. 26, 2018 with the deposit number CGMCC No. 15650. The bacteria have gastric acid resistance and intestinal fluid resistance, can significantly promote the growth of Bifidobacterium and Lactobacillus, significantly increase antibody-producing cells and half hemolysis value HC50, activate NK cell activity, and can be used to prepare foods for immunity enhancement. It also has the effects in preventing osteoporosis, increasing blood calcium and/or phosphorus ions, which has a wide range of application prospects.

Abstract: A Bifidobacterium lactis BL-99 strain capable of enhancing immunity and the use thereof, which belongs to the technical field of microorganisms, is described. The Bifidobacterium lactis BL-99 provided by the present invention is deposited in China General Microbiological Culture Collection Center CGMCC on Apr. 26, 2018 with the deposit number CGMCC No. 15650. The bacteria have gastric acid resistance and intestinal fluid resistance, can significantly promote the growth of Bifidobacterium and Lactobacillus, significantly increase antibody-producing cells and half hemolysis value HC50, activate NK cell activity, and can be used to prepare foods for immunity enhancement. It also has the effects in preventing osteoporosis, increasing blood calcium and/or phosphorus ions, which has a wide range of application prospects.

Abstract: The present disclosure provides a composition comprising Bifidobacterium lactis and human milk oligosaccharides (HMOs) and use thereof. The composition is capable of effectively enhancing resistance of an organism to Staphylococcus aureus infection, improving innate immunity of an organism, and/or anti-aging, and can be added to various health foods and healthcare foods.

Abstract: The present disclosure provides human milk oligosaccharide for improving the health of intestinal microenvironment and the use thereof. Specifically, the present disclosure provides the use of human milk oligosaccharide, especially the fucosyl-based oligosaccharide 2?-FL or 3-FL in the preparation of a food for improving the health of the intestinal microenvironment, wherein the improving the health of the intestinal microenvironment includes: functioning as prebiotics in the intestinal system that are used by intestinal flora to produce gas, lowering pH to maintain the health of the intestinal microenvironment, and/or reducing branched chain fatty acids such as isobutyric acid and/or isovaleric acid.

Abstract: A new use of Lactobacillus paracasei subsp. paracasei K56 capable of regulating the gastrointestinal flora balance is described. The deposit number of the Lactobacillus paracasei subsp. paracasei is DSM27447. This strain alone has the ability to significantly promote the growth of intestinal Bifidobacterium and Lactobacillus, suppress Desulfovibrio and/or Enterobacteria in the intestine, suppress Helicobacter and/or Escherichia-Shigella, and can endure a simulated in vitro gastrointestinal fluid stress environment. Experiments in mice show that this strain has no acute oral toxicity, no antibiotic resistance, and may be safely used in food processing.

Abstract: The present invention relates to the field of food and pharmaceutical products, and specifically to human milk oligosaccharide for improving resistance of organism against Staphylococcus aureus infection. In particular, the present invention relates to use of human milk oligosaccharide in preparation of a nutritional composition or medicament for prevention and/or treatment of diseases associated with Staphylococcus aureus infection in individuals, or for alleviation of discomfort associated with Staphylococcus aureus infection, or for improvement of an individual's resistance against Staphylococcus aureus infection, or for improvement of an individual's innate immunity and/or anti-aging.

Abstract: A Bifidobacterium lactis BL-99 strain capable of enhancing immunity and the use thereof, which belongs to the technical field of microorganisms, is described. The Bifidobacterium lactis BL-99 provided by the present invention is deposited in China General Microbiological Culture Collection Center CGMCC on Apr. 26, 2018 with the deposit number CGMCC No. 15650. The bacteria have gastric acid resistance and intestinal fluid resistance, can significantly promote the growth of Bifidobacterium and Lactobacillus, significantly increase antibody-producing cells and half hemolysis value HC50, activate NK cell activity, and can be used to prepare foods for immunity enhancement. It also has the effects in preventing osteoporosis, increasing blood calcium and/or phosphorus ions, which has a wide range of application prospects.

Abstract: A Bifidobacterium lactis BL-99 strain capable of enhancing immunity and the use thereof, which belongs to the technical field of microorganisms, is described. The Bifidobacterium lactis BL-99 provided by the present invention is deposited in China General Microbiological Culture Collection Center CGMCC on Apr. 26, 2018 with the deposit number CGMCC No. 15650. The bacteria have gastric acid resistance and intestinal fluid resistance, can significantly promote the growth of Bifidobacterium and Lactobacillus, significantly increase antibody-producing cells and half hemolysis value HC50, activate NK cell activity, and can be used to prepare foods for immunity enhancement. It also has the effects in preventing osteoporosis, increasing blood calcium and/or phosphorus ions, which has a wide range of application prospects.

Abstract: A Bifidobacterium lactis BL-99 strain capable of enhancing immunity and the use thereof, which belongs to the technical field of microorganisms, is described. The Bifidobacterium lactis BL-99 provided by the present invention is deposited in China General Microbiological Culture Collection Center CGMCC on Apr. 26, 2018 with the deposit number CGMCC No. 15650. The bacteria have gastric acid resistance and intestinal fluid resistance, can significantly promote the growth of Bifidobacterium and Lactobacillus, significantly increase antibody-producing cells and half hemolysis value HC50, activate NK cell activity, and can be used to prepare foods for immunity enhancement. It also has the effects in preventing osteoporosis, increasing blood calcium and/or phosphorus ions, which has a wide range of application prospects.

Abstract: The present application relates to a Lactobacillus paracasei ET-22 strain and use thereof. The present application provides a Lactobacillus paracasei ET-22 strain with a deposit number of CGMCC No. 15077, a composition containing the strain and a method of treating a subject using the strain. The present application also relates to a method for treating a subject, including administering an effective amount of the Lactobacillus paracasei ET-22 strain to a subject in need thereof for 1) whitening teeth and/or inhibiting oral pathogens; 2) adjusting balance of flora in the subject; 3) promoting growth of bifidobacteria and/or lactic acid bacteria; and/or 4) enhancing immunity of the subject.

Abstract: The present application relates to a Lactobacillus paracasei ET-22 strain and use thereof. The present application provides a Lactobacillus paracasei ET-22 strain with a deposit number of CGMCC No. 15077, a composition containing the strain and a method of treating a subject using the strain. The present application also relates to a method for treating a subject, including administering an effective amount of the Lactobacillus paracasei ET-22 strain to a subject in need thereof for 1) whitening teeth and/or inhibiting oral pathogens; 2) adjusting balance of flora in the subject; 3) promoting growth of bifidobacteria and/or lactic acid bacteria; and/or 4) enhancing immunity of the subject.

Abstract: A Bifidobacterium lactis BL-99 strain capable of enhancing immunity and the use thereof, which belongs to the technical field of microorganisms, is described. The Bifidobacterium lactis BL-99 provided by the present invention is deposited in China General Microbiological Culture Collection Center CGMCC on Apr. 26, 2018 with the deposit number CGMCC No. 15650. The bacteria have gastric acid resistance and intestinal fluid resistance, can significantly promote the growth of Bifidobacterium and Lactobacillus, significantly increase antibody-producing cells and half hemolysis value HC50, activate NK cell activity, and can be used to prepare foods for immunity enhancement. It also has the effects in preventing osteoporosis, increasing blood calcium and/or phosphorus ions, which has a wide range of application prospects.

Abstract: A new use of Lactobacillus paracasei subsp. paracasei K56 capable of regulating the gastrointestinal flora balance is described. The deposit number of the Lactobacillus paracasei subsp. paracasei is DSM27447. This strain alone has the ability to significantly promote the growth of intestinal Bifidobacterium and Lactobacillus, suppress Desulfovibrio and/or Enterobacteria in the intestine, suppress Helicobacter and/or Escherichia-Shigella, and can endure a simulated in vitro gastrointestinal fluid stress environment. Experiments in mice show that this strain has no acute oral toxicity, no antibiotic resistance, and may be safely used in food processing.